Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MIF | P14174 | 2/20 | 0.52 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938440 | 1.00 | RAB9A (0.63) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL22649388 | 0.89 | SMN1; SMN2 (0.62) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL14938473 | 0.88 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL14938474 | 0.88 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL14938480 | 0.85 | ALDH1A1 (0.65) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL14938482 | 0.85 | ALDH1A1 (0.65) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL16908701 | 0.85 | NPC1 (0.55) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL15431449 | 0.84 | KMT2A (0.58) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL15672276 | 0.82 | LMNA (0.82) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL14950299 | 0.81 | RAB9A (0.49) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4559906-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-05-08 | — | — | US | disclosed |
| WO-2024261257-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024019103-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-01-25 | — | — | WO | disclosed |
| WO-2013067646-A1 | PROCESS FOR THE SYNTHESIS OF BETA-AMINOCARBONYLS | UNIVERSITY OF OTTAWA (CA) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013067646-A1 | PROCESS FOR THE SYNTHESIS OF BETA-AMINOCARBONYLS | UNIVERSITY OF OTTAWA (CA) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | RAB9A 50/4885SMN1; SMN2 2870/4885NPC1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.